{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:15:11Z","timestamp":1760242511596},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,9,24]],"date-time":"2010-09-24T00:00:00Z","timestamp":1285286400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s12032-010-9628-7","type":"journal-article","created":{"date-parts":[[2010,9,23]],"date-time":"2010-09-23T19:56:15Z","timestamp":1285271775000},"page":"1196-1200","source":"Crossref","is-referenced-by-count":11,"title":["Nephrotic syndrome induced by pamidronate"],"prefix":"10.1007","volume":"28","author":[{"given":"M. A. G. J.","family":"ten Dam","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. B.","family":"Hilbrands","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. F. M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,9,24]]},"reference":[{"issue":"8","key":"9628_CR1","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","volume":"334","author":"JR Berenson","year":"1996","unstructured":"Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334(8):488\u201393.","journal-title":"N Engl J Med"},{"issue":"6","key":"9628_CR2","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","volume":"16","author":"GN Hortobagyi","year":"1998","unstructured":"Hortobagyi GN, Theriault RL, Lipton A, et al. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998;16(6):2038\u201344.","journal-title":"J Clin Oncol"},{"issue":"5","key":"9628_CR3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.urology.2005.05.035","volume":"66","author":"TJ Polascik","year":"2005","unstructured":"Polascik TJ, Given RW, Metzger C, et al. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases. Urology. 2005;66(5):1054\u20139.","journal-title":"Urology"},{"issue":"32","key":"9628_CR4","doi-asserted-by":"crossref","first-page":"8219","DOI":"10.1200\/JCO.2005.02.9579","volume":"23","author":"MD Michaelson","year":"2005","unstructured":"Michaelson MD, Smith MR. Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol. 2005;23(32):8219\u201324.","journal-title":"J Clin Oncol"},{"issue":"6","key":"9628_CR5","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1093\/annonc\/mdj105","volume":"17","author":"T Tanvetyanon","year":"2006","unstructured":"Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006;17(6):897\u2013907.","journal-title":"Ann Oncol"},{"key":"9628_CR6","unstructured":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39(2 Suppl 1):S1\u2013S266."},{"issue":"2","key":"9628_CR7","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1053\/j.ajkd.2003.10.024","volume":"43","author":"VD D\u2019Agati","year":"2004","unstructured":"D\u2019Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004;43(2):368\u201382.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"9628_CR8","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1053\/snep.2003.50019","volume":"23","author":"JA Schwimmer","year":"2003","unstructured":"Schwimmer JA, Markowitz GS, Valeri A, Appel GB. Collapsing glomerulopathy. Semin Nephrol. 2003;23(2):209\u201318.","journal-title":"Semin Nephrol"},{"issue":"1","key":"9628_CR9","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ndt\/gfm523","volume":"23","author":"JK Deegens","year":"2008","unstructured":"Deegens JK, Steenbergen EJ, Borm GF, Wetzels JF. Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population\u2013epidemiology and outcome. Nephrol Dial Transplant. 2008;23(1):186\u201392.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"9628_CR10","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1681\/ASN.V1261164","volume":"12","author":"GS Markowitz","year":"2001","unstructured":"Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12(6):1164\u201372.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"9628_CR11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1046\/j.1365-2141.2002.03826.x","volume":"119","author":"R Desikan","year":"2002","unstructured":"Desikan R, Veksler Y, Raza S, et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol. 2002;119(2):496\u20139.","journal-title":"Br J Haematol"},{"issue":"3","key":"9628_CR12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1093\/ndt\/gfg567","volume":"19","author":"M Kunin","year":"2004","unstructured":"Kunin M, Kopolovic J, Avigdor A, Holtzman EJ. Collapsing glomerulopathy induced by long-term treatment with standard-dose pamidronate in a myeloma patient. Nephrol Dial Transplant. 2004;19(3):723\u20136.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"9628_CR13","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1523-1755.2004.00426.x","volume":"65","author":"YM Barri","year":"2004","unstructured":"Barri YM, Munshi NC, Sukumalchantra S, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int. 2004;65(2):634\u201341.","journal-title":"Kidney Int"},{"issue":"3","key":"9628_CR14","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08998280.2007.11928298","volume":"20","author":"M Shreedhara","year":"2007","unstructured":"Shreedhara M, Fenves AZ, Benavides D, Stone MJ. Reversibility of pamidronate-associated glomerulosclerosis. Proc (Bayl Univ Med Cent). 2007;20(3):249\u201353.","journal-title":"Proc (Bayl Univ Med Cent)"},{"key":"9628_CR15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nephro.2008.08.013","volume":"5","author":"V Jotterand","year":"2009","unstructured":"Jotterand V, Moll S, Martin P-Y, Saudan P. Bisphosphonates-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review. Nephrologie & Therapeutique. 2009;5:134.","journal-title":"Nephrologie & Therapeutique"},{"issue":"3","key":"9628_CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MAJ.0b013e318184e741","volume":"338","author":"M Nagahama","year":"2009","unstructured":"Nagahama M, Sica DA. Pamidronate-induced kidney injury in a patient with metastatic breast cancer. Am J Med Sci. 2009;338(3):225\u20138.","journal-title":"Am J Med Sci"},{"issue":"5","key":"9628_CR17","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/ajkd.2002.32797","volume":"39","author":"GS Markowitz","year":"2002","unstructured":"Markowitz GS, Fine PL, D\u2019Agati VD. Nephrotic syndrome after treatment with pamidronate. Am J Kidney Dis. 2002;39(5):1118\u201322.","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"9628_CR18","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5414\/CNP67263","volume":"67","author":"N Gokden","year":"2007","unstructured":"Gokden N, Zangari M, Elici F, Barlogie B, Kumar J. Potential effect of zoledronate therapy in heavy proteinuria. Clin Nephrol. 2007;67(4):263\u20135.","journal-title":"Clin Nephrol"},{"issue":"10","key":"9628_CR19","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s00198-007-0361-9","volume":"18","author":"J Pascual","year":"2007","unstructured":"Pascual J, Torrealba J, Myers J, et al. Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. Osteoporos Int. 2007;18(10):1435\u20138.","journal-title":"Osteoporos Int"},{"issue":"8","key":"9628_CR20","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1093\/ndt\/gfm209","volume":"22","author":"M Bodmer","year":"2007","unstructured":"Bodmer M, Amico P, Mihatsch MJ, et al. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant. 2007;22(8):2366\u201370.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"9628_CR21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s002239900606","volume":"64","author":"E Hiroi-Furuya","year":"1999","unstructured":"Hiroi-Furuya E, Kameda T, Hiura K, et al. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int. 1999;64(3):219\u201323.","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"9628_CR22","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1053\/j.ajkd.2006.02.189","volume":"47","author":"M Sauter","year":"2006","unstructured":"Sauter M, Julg B, Porubsky S, et al. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis. 2006;47(6):1075\u201380.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"9628_CR23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1046\/j.1523-1755.2003.00071.x","volume":"64","author":"GS Markowitz","year":"2003","unstructured":"Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int. 2003;64(1):281\u20139.","journal-title":"Kidney Int"},{"issue":"1","key":"9628_CR24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5414\/CNP61063","volume":"61","author":"S Smetana","year":"2004","unstructured":"Smetana S, Michlin A, Rosenman E, Biro A, Boaz M, Katzir Z. Pamidronate-induced nephrotoxic tubular necrosis\u2013a case report. Clin Nephrol. 2004;61(1):63\u20137.","journal-title":"Clin Nephrol"},{"issue":"4","key":"9628_CR25","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/ndt\/gfg044","volume":"18","author":"M Buysschaert","year":"2003","unstructured":"Buysschaert M, Cosyns JP, Barreto L, Jadoul M. Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant. 2003;18(4):826\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"9628_CR26","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1159\/000046123","volume":"89","author":"DK Janssen van","year":"2001","unstructured":"Janssen van DK, Neyns B, Van der NP, Verbeelen D. Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bone metastases. Nephron. 2001;89(4):467\u20138.","journal-title":"Nephron"},{"issue":"8","key":"9628_CR27","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","volume":"98","author":"LS Rosen","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003;98(8):1735\u201344.","journal-title":"Cancer"},{"issue":"10","key":"9628_CR28","first-page":"524","volume":"4","author":"RS McDermott","year":"2006","unstructured":"McDermott RS, Kloth DD, Wang H, Hudes GR, Langer CJ. Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive model. J Support Oncol. 2006;4(10):524\u20139.","journal-title":"J Support Oncol"},{"key":"9628_CR29","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00520-008-0553-7","volume":"17","author":"IJ Diel","year":"2009","unstructured":"Diel IJ, Weide R, K\u00f6ppler H, et al. Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical record review. Support Care Cancer. 2009;17:719\u201325.","journal-title":"Support Care Cancer"},{"key":"9628_CR30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000096056","volume":"29","author":"R Bergner","year":"2006","unstructured":"Bergner R, Diel IJ, Henrich D, Hoffman M, Uppenkamp M. Differences in nephrotoxicity of intravenous bisphophonates for the treatment of malignancy related bone disease. Onkologie. 2006;29:534\u201340.","journal-title":"Onkologie"},{"key":"9628_CR31","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1634\/theoncologist.10-90001-3","volume":"19","author":"JJ Body","year":"2005","unstructured":"Body JJ, Pfister T, Bauss F. Preclinical perspectives on bisphosphonate renal safety. Oncologist. 2005;19:3\u20137.","journal-title":"Oncologist"},{"issue":"17","key":"9628_CR32","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","volume":"25","author":"American Society of Clinical Oncology","year":"2007","unstructured":"American Society of Clinical Oncology. Clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol. 2007;25(17):2464\u201372.","journal-title":"J Clin Oncol"},{"issue":"12","key":"9628_CR33","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1359\/JBMR.050817","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res. 2005;20(12):2105\u201315.","journal-title":"J Bone Miner Res"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9628-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-010-9628-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-010-9628-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T14:40:54Z","timestamp":1636555254000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-010-9628-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,24]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["9628"],"URL":"https:\/\/doi.org\/10.1007\/s12032-010-9628-7","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,24]]}}}